HeartLogic Diagnostic for Heart Failure

(Heartlogic ISR Trial)

This trial tests whether HeartLogic, a special alert system, can help people with heart failure avoid hospital visits and improve overall well-being. HeartLogic sends alerts that assist doctors in deciding when to adjust treatments. The trial includes two groups: one with HeartLogic alerts set to a lower threshold for action and another with standard settings. This trial suits individuals with heart failure who have been hospitalized in the past two years and use a specific heart device called an ICD or CRT-D. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance heart failure management.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the HeartLogic Diagnostic is generally safe for patients with heart failure. Studies have found that it can effectively predict heart failure episodes without causing significant harm. For instance, one study found that the system rarely gives false alarms, with only about 1.18 incorrect alerts per year, minimizing unnecessary worry for patients.

Moreover, real-world evidence indicates that the HeartLogic system consistently detects heart failure events. It has reduced the number of worsening heart failure episodes compared to standard care, suggesting the system is not only safe but also helpful in managing heart failure.

Researchers are excited about the HeartLogic Diagnostic for heart failure because it offers a proactive approach to managing the condition. Unlike standard treatments that often rely on patient-reported symptoms or routine check-ups, HeartLogic uses advanced algorithms to detect subtle changes in the heart's function, potentially catching issues before they become severe. This early detection system enables timely interventions, which could lead to better patient outcomes and possibly reduce hospitalizations. By setting a lower threshold for triggering treatment adjustments, it aims to provide more personalized and precise care compared to traditional methods.

Studies have shown that the HeartLogic Diagnostic can effectively predict heart failure events by analyzing factors like chest fluid levels and daily activity. One study found that it correctly identified heart failure issues 78.3% of the time, with a low false alert rate of about 1.18 times per year per patient. In this trial, participants in the Active Treatment Arm will have the HeartLogic threshold set to 10, triggering a treatment algorithm. This approach may lead to fewer heart failure problems compared to the Control Arm, which follows standard care. HeartLogic thus emerges as a promising tool for managing heart failure.¹⁴⁶⁷⁸